New York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Tvardi Therapeutics, Inc. ("Tvardi Therapeutics, Inc.") (NASDAQ: TVRD) concerning possible violations of federal securities laws.On October 13, 2025, Tvardi reported data from its Phase 2 REVERT study testing its STAT3 inhibitor drug, TTI-101, to treat patients with idiopathic pulmonary fibrosis (IPF). The company reported that "the study did not meet its goals," as the " ...